May 18 (Reuters) – The U.S. Food and Drug Administration on
Wednesday approved Roche Holding AG’s immunotherapy for
the most common form of bladder cancer.
The post U.S. FDA approves Roche’s immunotherapy for bladder cancer appeared first on NASDAQ.